Efficacy and tolerability of intramuscular and oral meloxicam in patients with acute lumbago: A comparison with intramuscular and oral piroxicam

Current Medical Research and Opinion

Volumn 14, Issue 1, 1997, Pages 29-38

  Bosch, Hans Christoph ^a   Sigmund, Ralf ^b   Hettlch, Marcellne ^b  

^a Boehringer Ingelheim GmbH ^*  (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Analgesic; COX 2; Lumbago; Meloxicam; Piroxicam; Side effects; Tolerability

Indexed keywords

ANALGESIC AGENT; MELOXICAM; PIROXICAM;

ABDOMINAL PAIN; ANALGESIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INJECTION SITE; INTRAMUSCULAR DRUG ADMINISTRATION; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MOVEMENT (PHYSIOLOGY); MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; OUTPATIENT; RANDOMIZED CONTROLLED TRIAL; RATING SCALE;

EID: 0031409321     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007999709113340     Document Type: Article

References (27)

1. Auvinet B, Ziller R, Appelboom, T and Vélicitat, P (1995). Comparison of the onset and intensity of action of intramuscular meloxicam and oral meloxicam in patients with acute sciatica. Clin. Ther., 17, 1078-1090.
2. Borenstein D (1993). Medical therapy of low back pain. Orthop. Rev., 22, 20-25.
3. Bullinger M, Kirchberger I and von Steinb̈chel N (1993). Der Fragebogen Alltagsleben - ein Verfahren zur Erfassung der gesundheitsbezogenen Lebensqualit@t. Z. Med. Psychol., 2, 121-131.
4. Cacace, L (1972). Elevated serum CPK after drug injections. N. Engl. J. Med., 287, 309-310.
5. Churchill L, Graham AG, Shin C-K, Pauletti D, Farina PR and Grob PM (1996). Selective inhibition of human cyclo-oxygenase-2 by meloxicam. Inflammopharma-cology, 4, 125135.
6. Colberg K, Hettich M, Sigmund R and Degner PL (1996). The efficacy and tolerability of an 8-day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. Curr. Med. Res, Opin., 13, 363-377.
7. Distel M, Mueller C, Bluhmki E and Fries J (1996). Safety of meloxicam: a global analysis of clinical trials. Br. J. Rheumatol., 35 (Suppl 1), 68-77.
8. Engelhardt G, Bögel R, Schnitzler Chr and Utzmann R (1996). Meloxicam: influence on arachidonic acid metabolism. Part I. In vitro findings. Biochem. Pharmacol., 31, 2128.
9. Engelhardt G, Bögel R, Schnitzler Chr and Utzmann R. (1996). Meloxicam: influence on arachidonic acid metabolism. Part II. In vivo findings. Biochem. Pharmacol., 31, 29-38.
10. Frank A (1993). Low back pain. Br. Med. J., 306, 901-909.
11. Fries JF (1991). NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J. Rheumatol, 18 (Suppl 28), 6-10.
12. Gabriel SE, Jaakkimainen L and Bombardier C (1991). Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann. Intern. Med., 115, 787-796.
13. Ghozlan PR, Bernhardt M, Vélicitat P and Bluhmki E (1996). Tolerability of multiple administration of intramuscular meloxicam: a comparison with intramuscular piroxicam in patients with rheumatoid arthritis or osteoarthritis. Br. J. Rheumatol., 35 (Suppl 1), 51-55.
14. Helfgott SM, Sandberg-Cook J, Zakim D and Nestler J (1990).Diclofenac-associated hepatotoxicity. J. Am. Med. Assoc., 264, 2660-2662.
15. Hosie J, Distel M and Bluhmki E (1996). Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium. Br. J. Rheumatol., 35 (Suppl 1), 39-43.
16. Langman MJS, Well J, Wainwright P, Lawson DH, Rawlins MD, Logan RFA, Murphy M, Vessey MP and Colin-Jones DG (1994). Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet, 343,1075-1078.
17. Lindén B, Distel M and Bluhmki E (1996). A double-blind study to compare the efficacy and safety of meloxicam 15mg with piroxicam 20 mg in patients with osteoarthritis of the hip. Br. J. Rheumatol., 35 (Suppl 1), 35-38.
18. Murray MD and Brater DC (1993). Renal toxkity of the nonsteroidal antiinflammatory drugs. Annu. Rev. Pharmacol. Toxicol, 32, 435-465.
19. Narjes H, Türck D, Busch U, Heinzel G and Nehmiz G (1996). Pharmacokinetics and tolerability of meloxicam after i.m. administration. Br. J. Clin. Pharmacol., 41, 135-139.
20. Pairet M and Engelhardt G (1996). Differential inhibition of COX-1 and COX-2 in vitro and pharmacological profile in vivo of NSAIDs. In: Vane J, Sotting J and Sotting R (eds). Improved Non-steroid Anti-inflammatory Drugs - COX-2 Enzyme Inhibitors. Kluwer, London, pp. 103-119.
21. Rao KV and Balakrishna N (1995). Feasibility of Broka's index for the nutritional status of adults. Indian J. Med. Res., 102, 173-178.
22. Türck D, Roth W and Busch U (1996). A review of the clinical pharmacokinetics of meloxicam. Br. J. Rheumatol, 35 (Suppl 1), 13-16.
23. Uthgenannt H (1979). Comparison of enteral loss of blood during oral administration of three non-steroidal antiinflammatory agents: diclofenac, feprazone and indomethacin. In: Hart FD (ed.), Feprazone: New Biological and Clinical Aspects, 9th European Congress on Rheumatology, Wiesbaden, 2-8 September, Exc. Med., 1079, p. 16.
24. Vaccarino V, Sirtori CR and Bufalino L (1989). Local and systemic tolerability of piroxicam after intramuscular administration in healthy volunteers. Curr. Ther. Res., 45, 1-13.
25. Vane J (1994). Towards a better aspirin. Nature, 367, 215-216.
26. Vane JR and Botting RM (1995). New insights into the mode of action of anti-inflammatory drugs. Inflamm. Res., 44,1-10.
27. Wojtulewski JA, Schattenkirchner M, Barceló P, Le Loët X, Bevis PJR, Bluhmki E and Distel M (1996). A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. Br. J. Rheumatol., 35 (Suppl 1), 22-28.